康众医疗股东减持股份计划公告深度解析
公告要点
- 减持主体：公司实际控制人、高级管理人员高鹏先生计划减持股份。
- 减持股份数量及比例：高鹏先生拟减持不超过1,022,300股，占公司总股本的1.16%。
- 减持方式：集中竞价最多减持881,290股，大宗交易最多减持141,010股。
- 减持时间：2026年6月15日至2026年9月14日。
- 股份来源：全部为IPO前取得股份。
- 减持原因：因自身资金需求。
- 承诺与限制：减持价格不得低于公司首次公开发行价格（如有除权除息，价格相应调整）；每年减持不得超过所持股份总数的25%；离职后半年内不得转让股份。
- 对公司控制权影响：本次减持不会导致公司实际控制人发生变化。
- 过去12个月减持情况：一致行动人康诚企管与宁波同驰曾合计减持4,700,000股。
- 减持计划风险提示：减持计划存在实施不确定性，减持时间、价格、数量等受市场环境影响。
详细解读
江苏康众数字医疗科技股份有限公司（康众医疗，证券代码：688607）于2026年5月25日发布股东减持股份计划公告，内容如下：
减持主体及背景
高鹏先生为康众医疗实际控制人、董事及高级管理人员，截至2026年5月22日持有公司4,110,000股，占总股本4.66%。其所持股份均为IPO前取得，限售期已于2024年2月1日届满，现已上市流通。
高鹏与JIANQIANG LIU为一致行动人，合计持有16,920,000股，占总股本19.2%。其中JIANQIANG LIU为第一大股东，持有12,810,000股（14.54%）。
减持计划细节
- 高鹏先生计划通过集中竞价及大宗交易方式，减持不超过1,022,300股（占总股本1.16%）。
- 减持时间为2026年6月15日—2026年9月14日。
- 减持方式具体为：集中竞价不超过881,290股，大宗交易不超过141,010股。
- 股份来源均为IPO前取得。
根据公告，公司实际控制人及一致行动人在过去12个月内也有减持行为。2025年11月10日，康诚企管与宁波同驰通过询价转让合计减持4,700,000股。
减持承诺与法律合规
- 高鹏先生承诺，在锁定期满后2年内减持价格不低于公司首次公开发行价格（如有除权除息，价格相应调整）。
- 在任期间，每年减持不超过所持股份总数的25%，离职后半年内不得转让所持股份。
- 减持方式包括集中竞价、大宗交易、协议转让及其他符合监管规定的方式。
- 减持不会影响公司控制权及持续经营稳定。
风险提示与影响
- 减持计划实施存在不确定性，减持时间、价格、数量等受市场环境影响。
- 本次减持不会导致公司实际控制人变更。
- 减持符合科创板及相关法律法规规定，公司将严格履行信息披露义务。
投资者需关注的重大事项
- 实际控制人减持：高鹏先生作为实际控制人减持股份，虽不会导致控制权变动，但对市场情绪可能产生一定影响。
- 价格敏感信息：减持价格不得低于发行价，减持数量、时间、方式均有严格限制，投资者需关注减持进度和公司公告。
- 资金需求原因：减持主要为个人资金需求，未涉及公司经营或战略调整。
- 历史减持情况：一致行动人近一年曾大额减持，显示高管及大股东对流动性有一定需求。
- 减持计划符合监管要求：投资者可放心公司治理与合规性，但需注意短期内股价波动风险。
可能对股价的影响分析
实际控制人及高管减持股份通常被市场认为是对公司未来发展信心的间接信号，可能影响投资者情绪，短期内或对股价造成一定压力。由于减持数量有限、价格有底线并不影响控制权，公司经营及治理结构不受重大影响，长期看影响有限。但投资者需密切关注减持进度、市场反应及公司后续公告。
免责声明
本文内容仅供投资者参考，不构成任何投资建议。投资者需根据自身情况及市场环境，理性判断和决策。公司及本人不对因本文内容所引起的投资结果承担任何法律责任。
English Version
Detailed Analysis of Kangzhong Medical Shareholder Share Reduction Plan Announcement
Key Points
- Reduction Subject: Company’s actual controller and senior executive Mr. Gao Peng plans to reduce holdings.
- Number and Proportion of Shares to be Reduced: Mr. Gao Peng intends to reduce no more than 1,022,300 shares, accounting for 1.16% of total share capital.
- Reduction Method: Up to 881,290 shares via centralized bidding, up to 141,010 shares via block trading.
- Reduction Period: From June 15, 2026 to September 14, 2026.
- Source of Shares: All shares obtained before the IPO.
- Reason for Reduction: Personal funding needs.
- Commitments and Restrictions: Reduction price must not be lower than the IPO price (adjusted for any ex-rights/ex-dividends); annual reduction not to exceed 25% of total holdings; no transfer within six months after resignation.
- Impact on Company Control: This reduction will not change the company’s actual controller.
- Past 12-Month Reduction: Associates Kangcheng Qiguan and Ningbo Tongchi reduced a total of 4,700,000 shares in the past year.
- Risk Warning: Implementation uncertainty; timing, price, and quantity of reduction depend on market conditions.
In-Depth Analysis
Jiangsu Kangzhong Digital Medical Technology Co., Ltd. (Kangzhong Medical, stock code: 688607) released a shareholder share reduction plan announcement on May 25, 2026, as follows:
Reduction Subject & Background
Mr. Gao Peng, Kangzhong Medical’s actual controller, director, and senior executive, held 4,110,000 shares as of May 22, 2026, accounting for 4.66% of total share capital. All shares were obtained before the IPO, with the lock-up period ending February 1, 2024, and now freely tradable.
Gao Peng and JIANQIANG LIU are acting in concert, jointly holding 16,920,000 shares (19.2%). JIANQIANG LIU is the largest shareholder (12,810,000 shares, 14.54%).
Reduction Plan Details
- Gao Peng plans to reduce no more than 1,022,300 shares (1.16% of total share capital) via centralized bidding and block trading.
- Reduction period: June 15, 2026—September 14, 2026.
- Centralized bidding: up to 881,290 shares; block trading: up to 141,010 shares.
- All shares are pre-IPO shares.
The announcement also notes that controlling shareholders and associates reduced 4.7 million shares through inquiry transfer in November 2025.
Commitment & Legal Compliance
- Reduction price not lower than IPO issue price (adjusted for ex-rights/ex-dividends).
- Annual reduction not to exceed 25% of total holdings during tenure; no transfer within six months of resignation.
- Reduction methods: centralized bidding, block trading, negotiated transfer, and others per regulatory rules.
- No impact on company control or stable operations.
Risk Warning & Impact
- Reduction plan implementation uncertain; timing, price, and quantity subject to market conditions.
- No change in company control after reduction.
- Reduction plan complies with STAR Market and relevant regulations; company will strictly fulfill disclosure obligations.
Key Matters for Investors
- Actual Controller Reduction: As actual controller, Mr. Gao Peng’s reduction may affect market sentiment even though control is unchanged.
- Price-sensitive Information: Reduction price has a floor; quantity, timing, and method strictly restricted. Investors should monitor reduction progress and company announcements.
- Reason: Reduction is solely for personal funding needs, not related to company operations or strategy.
- History: Associates have reduced large holdings in the past year, suggesting liquidity needs among top holders.
- Regulatory Compliance: Investors can be assured of company governance and compliance, but should watch for short-term price volatility.
Potential Impact on Share Price
Reduction by actual controller and senior executives is often seen as a signal of confidence in the company’s future, potentially affecting investor sentiment and exerting short-term pressure on share price. Since reduction is limited in number, price is protected, and control is unaffected, company operations and governance remain stable, and long-term impact is limited. Investors should closely watch reduction progress, market response, and subsequent announcements.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make rational decisions based on their own circumstances and market conditions. Neither the company nor the author shall be liable for any investment results arising from the content herein.
